SCHEMBL4473726

SCHEMBL4473726

Oc1cccc2c1OCC1(CCC1)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.35
BCL2L1 Q07817 1/20 0.34
BAD Q92934 1/20 0.34
MAPT P10636 4/20 0.34
TDP1 Q9NUW8 4/20 0.34
KDM4E B2RXH2 3/20 0.34
HPGD P15428 3/20 0.34
RECQL P46063 3/20 0.34
ALDH1A1 P00352 3/20 0.34
CYP3A4 P08684 3/20 0.34
HSD17B10 Q99714 3/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
G6PD P11413 2/20 0.34
MAPK1 P28482 2/20 0.34
TSHR P16473 2/20 0.34
MEN1 O00255 2/20 0.34
ALOX15 P16050 2/20 0.34
KMT2A Q03164 2/20 0.34
KDR P35968 2/20 0.34
NSD2 O96028 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4479211 0.74 CYP1A2 (0.36) MAPTTDP1KDM4EHPGDRECQL
SCHEMBL4464566 0.71 AKT1 (0.36) MAPTTDP1KDM4EHPGDRECQL
SCHEMBL6465805 0.68
SCHEMBL11704797 0.67 BCL2L1 (0.46) DRD2BCL2L1BADMAPTTDP1
SCHEMBL4468522 0.67 ENTPD5 (0.40) MAPTKDM4EHPGDALDH1A1CYP3A4
SCHEMBL7517744 0.66 BCL2L1 (0.48) DRD2BCL2L1BADMAPTTDP1
SCHEMBL2052908 0.65 PARP1 (0.56) DRD2BCL2L1BADMAPTTDP1
SCHEMBL15720982 0.65 TSHR (0.41) ALDH1A1TSHRPOLBSMN1; SMN2HRH3
SCHEMBL15485106 0.65 LMNA (0.51) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL28507933 0.65 BCL2L1 (0.52) DRD2BCL2L1BADMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 DRD2 3489/4885BCL2L1 2227/4885BAD 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.